Cerene (device for the treatment of menstrual bleeding)

History

2022: Entering the Russian market

In early May 2022, the medical and technological company Channel Medsystems announced the Cerene cryotherapy device for the treatment of abundant menstrual bleeding. The technology is designed to provide effective treatment of copious menstrual bleeding, the procedure can be carried out in the doctor's office in just a few minutes and which does not require general anesthesia.

Abundant menstrual bleeding is usually treated with medication, hormone therapy, hysterectomy, or endometrial ablation using cooling or heating techniques. Symptoms may include bleeding lasting more than seven days, soaking more than one pad or tampon per hour, or persistent lower abdominal pain during menstruation.

The Cerene cryotherapy device is approved for ablation. The procedure is well tolerated and provides relief of menstruation, significantly reducing abundant bleeding and spasms, thereby improving the quality of life. Importantly, Cerene retains the ability to access the uterine cavity for the diagnosis and treatment of intrauterine diseases after treatment.

The Cerene procedure uses cryotherapy, or cooling technology, to remove the lining of the uterus, known as the endometrium, which often causes severe bleeding and discomfort. Since monthly detachment of the endometrium causes menstrual bleeding, removal of the lining layer in the uterine cavity can lead to a reduction or absence of menstrual bleeding and spasms.

Cerene cryotherapy is a 2.5-minute procedure that is part of a 7-minute procedure that can be performed in a comfortable and familiar environment in the doctor's office without the need for general anesthesia. Unlike heat-based ablation technologies, Cerene uses cryotherapy, which provides a natural painkiller or numbness effect during treatment. It may take several months to see the full results of the treatment. At 12 months post-treatment, 90% of patients had normal, mild or absent monthly, and were satisfied with the treatment, and the results persisted 36 months after treatment, the developers said.^[1]